Sharp Therapeutics Corp.
SHRX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Net Income | 8.53% | -- | -- | -- | |
| Total Depreciation and Amortization | -12.24% | -- | -- | -- | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | -138.74% | -- | -- | -- | |
| Change in Net Operating Assets | -62.23% | -- | -- | -- | |
| Cash from Operations | -84.35% | -- | -- | -- | |
| Capital Expenditure | -38.46% | -- | -- | -- | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -- | -- | -- | -- | |
| Cash from Investing | 11.54% | -- | -- | -- | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -118.40% | -- | -- | -- | |
| Issuance of Common Stock | 108.17% | -- | -- | -- | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -- | -- | -- | -- | |
| Cash from Financing | 207.96% | -- | -- | -- | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | 1,361.81% | -- | -- | -- | |